Filtered By:
Source: European Heart Journal
Condition: Bleeding

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 74 results found since Jan 2013.

Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
Conclusion Betrixaban was well tolerated and had similar or lower rates of bleeding compared with well-controlled warfarin in patients with AF at risk for stroke.
Source: European Heart Journal - May 21, 2013 Category: Cardiology Authors: Connolly, S. J., Eikelboom, J., Dorian, P., Hohnloser, S. H., Gretler, D. D., Sinha, U., Ezekowitz, M. D. Tags: Arrhythmia/electrophysiology Source Type: research

Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome
Conclusion In this contemporary, large real-life ACS population, DAPT for more than 3 months compared with a shorter duration was associated with a lower risk of death, stroke, or re-infarction. Trial Registration Clinicaltrials.gov (NCT01623700).
Source: European Heart Journal - April 14, 2014 Category: Cardiology Authors: Varenhorst, C., Jensevik, K., Jernberg, T., Sundstrom, A., Hasvold, P., Held, C., Lagerqvist, B., James, S. Tags: FASTTRACK CLINICAL RESEARCH Source Type: research

Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis
Conclusions The SAPIEN 3 THV system was associated with low rates of 30-day mortality and major/disabling stroke as well as low rates of moderate or severe paravalvular regurgitation. Trial Registration ClinicalTrials.gov #NCT01314313.
Source: European Heart Journal - July 20, 2016 Category: Cardiology Authors: Kodali, S., Thourani, V. H., White, J., Malaisrie, S. C., Lim, S., Greason, K. L., Williams, M., Guerrero, M., Eisenhauer, A. C., Kapadia, S., Kereiakes, D. J., Herrmann, H. C., Babaliaros, V., Szeto, W. Y., Hahn, R. T., Pibarot, P., Weissman, N. J., Leip Tags: TAVI Source Type: research

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
ConclusionUninterrupted edoxaban therapy represents an alternative to uninterrupted VKA treatment in patients undergoing AF ablation.
Source: European Heart Journal - April 11, 2019 Category: Cardiology Source Type: research

Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials
ConclusionAfter second-generation DES implantation, 1 –3 months of DAPT followed by P2Y12 inhibitor SAPT is associated with lower major bleeding and similar stent thrombosis, all-cause death, myocardial infarction, and stroke compared with prolonged DAPT. Whether P2Y12 inhibitor SAPT is preferable to aspirin SAPT needs further investigation.
Source: European Heart Journal - December 7, 2020 Category: Cardiology Source Type: research

Urgent surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic heart valve thrombosis: a systematic review and meta-analysis of observational studies
Conclusion Urgent surgery was not superior to FT at restoring valve function, but substantially reduced the occurrence of thrombo-embolic events, major bleeding, and recurrent PVT. In experienced centres, urgent surgery should probably be preferred over FT for treating left-sided PVT, pending the results of randomized controlled trials.
Source: European Heart Journal - June 1, 2013 Category: Cardiology Authors: Karthikeyan, G., Senguttuvan, N. B., Joseph, J., Devasenapathy, N., Bahl, V. K., Airan, B. Tags: Valvular heart disease Source Type: research

EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary
New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients will have to learn how to use these drugs effectively and safely in specific clinical situations. This text is an executive summary of a practical guide that the European Heart Rhythm Association (EHRA) has assembled to help physicians in the use of the different NOACs. The full text is being published in EP Europace. Practical answers have been formulated for 15 concrete clinical scenarios: (i) practical start-up and follow-up scheme for ...
Source: European Heart Journal - July 14, 2013 Category: Cardiology Authors: Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., Kirchhof, P. Tags: SPECIAL ARTICLE Source Type: research

Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?
Low-dose aspirin has been shown to be effective in preventing about one-fifth of atherothrombotic vascular complications (non-fatal myocardial infarction, non-fatal stroke, or vascular death) in a meta-analysis of 16 secondary prevention trials in patients with previous myocardial infarction, stroke, or transient cerebral ischaemia. This corresponds to an absolute reduction of about 10–20 per 1000 patients in the yearly incidence of non-fatal events, and to a smaller, but still definite, reduction in vascular death. Against this benefit, the absolute increase in major extracranial bleeding complications [mostly, gast...
Source: European Heart Journal - November 21, 2013 Category: Cardiology Authors: Patrono, C. Tags: Controversies in cardiovascular medicine Source Type: research

Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial
Conclusion The efficacy and safety of apixaban compared with aspirin is consistent in subgroups of patients who have previously attempted but failed VKA therapy, irrespective of the reason for discontinuation.
Source: European Heart Journal - July 21, 2014 Category: Cardiology Authors: Coppens, M., Synhorst, D., Eikelboom, J. W., Yusuf, S., Shestakovska, O., Connolly, S. J. Tags: Atrial fibrillation Source Type: research

Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction
Conclusion In this randomized trial of STEMI patients, we were unable to demonstrate significant differences in net clinical outcome between prasugrel plus bivalirudin and clopidogrel plus heparin. Neither the composite of ischaemic complications nor bleeding were favourably affected by prasugrel plus bivalirudin compared with a regimen of clopidogrel plus unfractionated heparin. However, the results must be interpreted in view of the premature termination of the trial. Clinical trial registration information Unique identifier NCT00976092 (www.clinicaltrials.gov).
Source: European Heart Journal - September 7, 2014 Category: Cardiology Authors: Schulz, S., Richardt, G., Laugwitz, K.-L., Morath, T., Neudecker, J., Hoppmann, P., Mehran, R., Gershlick, A. H., Tolg, R., Anette Fiedler, K., Abdel-Wahab, M., Kufner, S., Schneider, S., Schunkert, H., Ibrahim, T., Mehilli, J., Kastrati, A., and for the Tags: FASTTRACK CLINICAL RESEARCH Source Type: research

Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)
Conclusion In this 1-year follow-up analysis of the EORP-AF pilot general registry, we provide data on the first contemporary registry focused on management practices among European cardiologists, conducted since the publication of the new ESC guidelines. Overall OAC use remains high, although persistence with therapy may be problematic. Nonetheless, continued OAC use was more common than in prior reports. Despite the high prescription of OAC, 1-year mortality and morbidity remain high in AF patients, particularly from heart failure and hospitalizations.
Source: European Heart Journal - December 14, 2014 Category: Cardiology Authors: Lip, G. Y. H., Laroche, C., Ioachim, P. M., Rasmussen, L. H., Vitali-Serdoz, L., Petrescu, L., Darabantiu, D., Crijns, H. J. G. M., Kirchhof, P., Vardas, P., Tavazzi, L., Maggioni, A. P., Boriani, G. Tags: Fast Track ESC Clinical Trial and Registry Update Source Type: research

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
Conclusion In patients undergoing CA for AF, the use of uninterrupted oral rivaroxaban was feasible and event rates were similar to those for uninterrupted VKA therapy. Name of the Trial Registry Clinicaltrials.gov trial registration number is NCT01729871.
Source: European Heart Journal - July 21, 2015 Category: Cardiology Authors: Cappato, R., Marchlinski, F. E., Hohnloser, S. H., Naccarelli, G. V., Xiang, J., Wilber, D. J., Ma, C.-S., Hess, S., Wells, D. S., Juang, G., Vijgen, J., Hugl, B. J., Balasubramaniam, R., De Chillou, C., Davies, D. W., Fields, L. E., Natale, A., on behalf Tags: Atrial fibrillation Source Type: research

A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial
Conclusion TriGuard cerebral protection during TAVI is safe and complete cerebral vessel coverage was achieved in 89% of subjects. In this exploratory study, subjects undergoing protected TAVI had more freedom from ischaemic brain lesions, fewer neurologic deficits, and improved cognitive function in some domains at discharge and 30 days compared with controls.
Source: European Heart Journal - August 14, 2015 Category: Cardiology Authors: Lansky, A. J., Schofer, J., Tchetche, D., Stella, P., Pietras, C. G., Parise, H., Abrams, K., Forrest, J. K., Cleman, M., Reinohl, J., Cuisset, T., Blackman, D., Bolotin, G., Spitzer, S., Kappert, U., Gilard, M., Modine, T., Hildick-Smith, D., Haude, M., Tags: FASTTRACK EuroPCR Source Type: research

Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial
Conclusions Patients randomized to the LDE treated with amiodarone at the time of randomization demonstrated a significant reduction in ischaemic events vs. warfarin when compared with those not on amiodarone, while preserving a favourable bleeding profile. In contrast, amiodarone had no effect on the relative efficacy and safety of HDE.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Steffel, J., Giugliano, R. P., Braunwald, E., Murphy, S. A., Atar, D., Heidbuchel, H., Camm, A. J., Antman, E. M., Ruff, C. T. Tags: Thrombosis and anti-thrombotic therapy Source Type: research

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation
Conclusions The five-element ORBIT bleeding risk score had better ability to predict major bleeding in AF patients when compared with HAS-BLED and ATRIA risk scores. The ORBIT risk score can provide a simple, easily remembered tool to support clinical decision making.
Source: European Heart Journal - December 7, 2015 Category: Cardiology Authors: O'Brien, E. C., Simon, D. N., Thomas, L. E., Hylek, E. M., Gersh, B. J., Ansell, J. E., Kowey, P. R., Mahaffey, K. W., Chang, P., Fonarow, G. C., Pencina, M. J., Piccini, J. P., Peterson, E. D. Tags: Atrial fibrillation Source Type: research